Business Context and Reporting Period
This Form 8-K was filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics) on December 15, 2021. The report details executive retention agreements and a new severance plan implemented during a leadership transition to new CEO Christopher Posner. The company is preparing for the commercial launch of KORSUVA (difelikefalin) in the United States for treating pruritus associated with chronic kidney disease.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation obligations.
- Cash Retention Bonuses: Total aggregate cash bonuses for five Named Executives amount to approximately $781,400.
- Individual Cash Bonuses:
- Thomas Reilly (CFO): $164,800
- Frédérique Menzaghi (CSO): $186,000
- Joana Goncalves (CMO): $186,000
- Scott Terrillion (General Counsel): $169,600
- Richard Makara (VP Accounting): $75,000
- Equity Grants: Restricted Stock Units (RSUs) were granted on December 17, 2021, with aggregate grant date values equal to the executives' 2021 target bonus amounts (or 85% for Mr. Makara).
Material Changes
The primary material change is the execution of Retention Agreements and a new Severance Plan for key executives to ensure stability during the CEO transition and the upcoming commercial launch of KORSUVA. This represents a new liability structure for executive compensation not previously disclosed in this specific format.
Guidance, Outlook, and Risks
Outlook: Management anticipates the commercial launch of KORSUVA injection in the U.S. within the next 18 months and continues development of an oral formulation.
Compensation Structure:
- Cash Payments: Paid in two equal installments; the second installment is contingent on continuous employment through December 15, 2022.
- RSU Vesting: 50% vests on December 15, 2022, and 50% on June 15, 2023, subject to continued service.
- Acceleration: Both cash bonuses (second installment) and RSUs accelerate upon termination without Cause or resignation for Good Reason on or before December 15, 2022, provided a general release is executed.
Severance Plan: A new plan provides cash severance (base salary for a defined period), prorated bonuses, and COBRA premiums for Covered Employees terminated without Cause or resigning for Good Reason. Benefits are enhanced if termination occurs within 12 months of a Change in Control.
Investor Verification Checklist
- Verify the total cash liability of approximately $781,400 and the timing of the second installment payments due in December 2022.
- Confirm the number of RSUs granted based on the 30-day average closing market price prior to the grant date.
- Review the full text of the Retention Agreements and Severance Plan (to be filed as exhibits to the 2021 Form 10-K) for specific definitions of "Cause" and "Good Reason."
- Monitor the commercial launch timeline for KORSUVA to assess the strategic necessity of these retention measures.